Investor Overview

Stock Information
Loading data...

Shares outstanding

121.2 million (as of 12/16/2022)

Press Releases
Jan 12, 2023

-- Phexxi is the first and only hormone-free contraceptive in the Favor product portfolio -- SAN DIEGO, Jan. 12, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that...

Jan 10, 2023

Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that Phexxi® (lactic acid, citric acid, potassium bitartrate) has been added to the Costco Member Prescription Program, giving millions of...

Jan 9, 2023

-- Medicaid improves Phexxi coverage for more than 3.7 million lives across 11 states -- -- Largest commercial insurer in Michigan and a marquis university plan in Pennsylvania move Phexxi to...

Dec 29, 2022

Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended September...

Oct 11, 2022

Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com.  

The U.S. contraceptive market was estimated at $7.9 billion as of 2021. Every 1% market share of the 42.2 million women in our addressable market represents more than $300 million in net product sales for Evofem.

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. The product is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.

Effective October 3, 2022, the Company's common stock trades on the OTCQB Venture Market under the ticker symbol "EVFM". 

Featured Event
Tuesday, October 25, 2022
11:35 am PDT

"Pregnancies by Acts of Intercourse with Vaginal pH Modulator: Results from the AMPOWER Study," was given as an oral presentation during the ASRM 2022 Scientific Congress.

View All

Latest Financial Results

Q2 2022, Ended June 30th, 2022

Earnings Release
Earnings Call
10-Q Filing
XBRL